Haha lets not get too crazy, this company has solid revenue growth and a decent product but it doesn't have the market dominance that is inherent with new marijuana biopharmaceutical companies. MYDX will run to .05 IMHO in the next fews months with good press but its going to need to put a huge amount of development into its other sensors before its even comparable
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.